A
Alcista
Alcista · 25%SRPT
$69.79
Precio del escenario
$17.790
+1.014 (+5.70%)Al cierre
Loading chart…
- Máximo
- 17.955
- Apertura
- 16.960
- Precio medio ponderado por volumen
- 17.45
- Volumen
- 4.04M
- Capitalización
- —
- Mínimo
- 16.610
- Importe
- 70.54M
- EV/EBITDA, TTM
- 10.02
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Análisis de IA of Sarepta Therapeutics Inc (SRPT)
MantenerSarepta Therapeutics Inc is currently priced at $17.85, which is below the average analyst price target of $25.6 (considering Mizuho and Jefferies targets). However, the RSI is at 42.686, indicating a neutral momentum, and the stock has seen a significant decline of 16.24% year-to-date. The main risk is the hedge funds selling, which has increased by 12693.27% over the last quarter, suggesting a lack of confidence in the stock's near-term performance.
Recomendaciones de analistas (18)
+16.92% de potencial alcista
Comprar
17 Comprar
1 Mantener
0 Vender
Actual: 17.79
Mínimo
5.00
Promedio
20.80
Máximo
45.00
RBC Capital
Sector Perform
$17
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$17
Sector Perform
JPMorgan
Neutral
$20
2026-09-30
JPMorgan
2026-09-30
Precio objetivo
$20
Neutral
Mizuho
Superar al mercado
$31
2026-09-08
Mizuho
2026-09-08
Precio objetivo
$31
Superar al mercado
Jefferies
Comprar
$30
2026-09-08
Jefferies
2026-09-08
Precio objetivo
$30
Comprar
H.C. Wainwright
Vender
$5
2026-09-08
H.C. Wainwright
2026-09-08
Precio objetivo
$5
Vender
Métricas de valoración
El PER previsto actual de Sarepta Therapeutics Inc (SRPT) es 19.16, frente a su media de 5 años de 9.03.
Escenarios de precio de Alphio AI para SRPT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SRPT en cartera
Cronología de eventos
Noticias
8.510-14NewsfilterSRP-1003 Demonstrates Breakthrough Efficacy in Treating Myotonic Dystrophy Type 1
6.510-05CNBCInvestor Perspectives on Multiple Companies
- 5.009-30Newsfilter
Sarepta Grants Equity Awards to New Employees
9.009-30NewsfilterSarepta's New Therapy Shows Breakthrough in Duchenne Muscular Dystrophy
- 8.509-25Newsfilter
Sarepta Presents New Data on Duchenne Muscular Dystrophy at WMS Congress
Preguntas frecuentes sobre SRPT, respondidas por Alphio AI
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Sarepta Therapeutics Inc is currently priced at $17.85, which is below the average analyst price target of $25.6 (considering Mizuho and Jefferies targets). However, the RSI is at 42.686, indicating a neutral momentum, and the stock has seen a significant decline of 16.24% year-to-date. The main risk is the hedge funds selling, which has increased by 12693.27% over the last quarter, suggesting a lack of confidence in the stock's near-term performance.
18 analysts cover SRPT: 17 rate it Buy, 1 Hold and 0 Sell. The average price target is 20.80.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.